Esophageal / gastroesophageal junction cancer: clinical trials in Switzerland
13 open trials in Switzerland for esophageal / gastroesophageal junction cancer and 17 open trials accepting several types of cancer, according to ClinicalTrials.gov, updated on October 27, 2026.
These results are indicative and do not replace medical advice — discuss them with your doctor.
Open trials
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111RecruitingPhase 1 · Phase 2
In Switzerland: Chur, Geneva
- A Beta-only IL-2 ImmunoTherapY Study
NCT05086692RecruitingPhase 1 · Phase 2
In Switzerland: Zurich
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730RecruitingPhase 1 · Phase 2
In Switzerland: Chur, Geneva
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944RecruitingPhase 1 · Phase 2
In Switzerland: Chur, Geneva
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
NCT07405151RecruitingPhase 1 · Phase 2
In Switzerland: Chur, Geneva
- Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
NCT07829081Recruiting
In Switzerland: Basel, Biel/Bienne, Lucerne
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972RecruitingPhase 1 · Phase 2
In Switzerland: Chur, Geneva
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632RecruitingPhase 1
In Switzerland: Chur, Lausanne
- Balloon Dilation in Patients Undergoing Minimally Invasive Ivor Lewis Esophagectomy and Its Effect on Reducing DGCE
NCT07355374Recruiting
In Switzerland: Basel
- PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
NCT05055648RecruitingPhase 3
In Switzerland: Villigen, Zurich
- Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NCT04498767Recruiting
In Switzerland: Bern, Zurich
- Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma
NCT03222635Recruiting
In Switzerland: Zurich
- Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC)
NCT06361043Recruiting
In Switzerland: Bern
Trials open to several types of cancer
These trials accept several types of cancer, perhaps yours: talk to your doctor about them.
- A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
NCT07785609RecruitingPhase 2
In Switzerland: Bellinzona, St. Gallen
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
NCT07793942Not yet recruitingPhase 2
In Switzerland: Lausanne, St. Gallen
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283RecruitingPhase 1
In Switzerland: Bellinzona, St. Gallen
- Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908RecruitingPhase 1
In Switzerland: Zurich
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819RecruitingPhase 2
In Switzerland: Bern, Geneva, Zurich
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483RecruitingPhase 1
In Switzerland: St. Gallen, Winterthur
- Safety and Early Signs of Efficacy of IL12-L19L19.
NCT04471987RecruitingPhase 1
In Switzerland: Basel, Bellinzona, Bern, Geneva
- A Nutrition and Exercise Program With Olanzapine Compared to Olanzapine Alone: A Trial in Patients With Advanced Tumors
NCT07722806Not yet recruitingPhase 2
In Switzerland: Winterthur
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324RecruitingPhase 1
In Switzerland: Bellinzona, Lausanne, St. Gallen
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
NCT07172919RecruitingPhase 2
In Switzerland: Basel
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626RecruitingPhase 1 · Phase 2
In Switzerland: Bellinzona, Lucerne
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
NCT06725758RecruitingPhase 1 · Phase 2
In Switzerland: Bellinzona
- First in Human Study of T3P-Y058-739 (T3P)
NCT05120596RecruitingPhase 1 · Phase 2
In Switzerland: Bern, Lausanne, Zurich
- Tumor Molecular Profiling in Early Phase Clinical Trials
NCT04510766Recruiting
In Switzerland: Bellinzona
- A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485RecruitingPhase 2
In Switzerland: Zurich
- Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
NCT06408688RecruitingPhase 4
In Switzerland: Baden, Basel, Liestal, St. Gallen
- INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
NCT03838042RecruitingPhase 1 · Phase 2
In Switzerland: Zurich